TY - JOUR
T1 - Fertility preservation for male patients with childhood, adolescent, and young adult cancer
T2 - recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
AU - Mulder, Renée L
AU - Font-Gonzalez, Anna
AU - Green, Daniel M
AU - Loeffen, Erik A H
AU - Hudson, Melissa M
AU - Loonen, Jacqueline
AU - Yu, Richard
AU - Ginsberg, Jill P
AU - Mitchell, Rod T
AU - Byrne, Julianne
AU - Skinner, Roderick
AU - Anazodo, Antoinette
AU - Constine, Louis S
AU - de Vries, Andrica
AU - Jahnukainen, Kirsi
AU - Lorenzo, Armando
AU - Meissner, Andreas
AU - Nahata, Leena
AU - Dinkelman-Smit, Marij
AU - Tournaye, Herman
AU - Haupt, Riccardo
AU - van den Heuvel-Eibrink, Marry M
AU - van Santen, Hanneke M
AU - van Pelt, Ans M M
AU - Dirksen, Uta
AU - den Hartogh, Jaap
AU - van Dulmen-den Broeder, Eline
AU - Wallace, W Hamish
AU - Levine, Jennifer
AU - Tissing, Wim J E
AU - Kremer, Leontien C M
AU - Kenney, Lisa B
AU - van de Wetering, Marianne D
N1 - Funding Information:
This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). RTM is supported by UK Research and Innovation Future Leaders Fellowship (MR/S017151/1). The Medical Research Council Centre for Reproductive Health is supported by Medical Research Council Centre Grant (MR/N022556/1). We thank Adam Glaser (University of Leeds, UK) and Zoltan Antal (Memorial Sloan Kettering Cancer Center, New York, NY, USA) for critically appraising the recommendations and manuscript as external reviewers. We also thank the PanCareLIFE Consortium (appendix p 2). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Funding Information:
This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). RTM is supported by UK Research and Innovation Future Leaders Fellowship (MR/S017151/1). The Medical Research Council Centre for Reproductive Health is supported by Medical Research Council Centre Grant (MR/N022556/1). We thank Adam Glaser (University of Leeds, UK) and Zoltan Antal (Memorial Sloan Kettering Cancer Center, New York, NY, USA) for critically appraising the recommendations and manuscript as external reviewers. We also thank the PanCareLIFE Consortium ( appendix p 2 ). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/2
Y1 - 2021/2
N2 - Male patients with childhood, adolescent, and young adult cancer are at an increased risk for infertility if their treatment adversely affects reproductive organ function. Future fertility is a primary concern of patients and their families. Variations in clinical practice are barriers to the timely implementation of interventions that preserve fertility. As part of the PanCareLIFE Consortium, in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in male patients who are diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. Recognising the need for global consensus, this clinical practice guideline used existing evidence and international expertise to rigorously develop transparent recommendations that are easy to use to facilitate the care of male patients with childhood, adolescent, and young adult cancer who are at high risk of fertility impairment and to enhance their quality of life.
AB - Male patients with childhood, adolescent, and young adult cancer are at an increased risk for infertility if their treatment adversely affects reproductive organ function. Future fertility is a primary concern of patients and their families. Variations in clinical practice are barriers to the timely implementation of interventions that preserve fertility. As part of the PanCareLIFE Consortium, in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in male patients who are diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. Recognising the need for global consensus, this clinical practice guideline used existing evidence and international expertise to rigorously develop transparent recommendations that are easy to use to facilitate the care of male patients with childhood, adolescent, and young adult cancer who are at high risk of fertility impairment and to enhance their quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85100103534&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(20)30582-9
DO - 10.1016/S1470-2045(20)30582-9
M3 - Review article
C2 - 33539754
SN - 1470-2045
VL - 22
SP - e57-e67
JO - LANCET ONCOLOGY
JF - LANCET ONCOLOGY
IS - 2
ER -